JAKARTA/BEIJING (INDONESIA/JAPAN) – A late-stage human trial, which involves as many as 1,620 patients in Indonesia was launched by China’s Sinovac Biotech Ltd on Tuesday. It is a trial for a COVID-19 vaccine candidate that China is developing with Indonesian state-owned peer Bio Farma.
Known as CoronaVac and previously PiCoVacc, it figures among the few potential vaccines that have made it to late-stage trials.
A late-stage trial of the same has already been going on in Brazil, estimated for as many as 9,000 people.
The Indonesia trial has brought in 1,215 people so far and will continue for six months.
Indonesia’s President Joko Widodo, said, “The threat of COVID-19 will not subside until a vaccine is given to all the people.”
In the Phase 2 clinical trial in China, which had 600 participants in China, it did not show any serious side effect. The rate of fever was comparatively low, the paper showed ahead of peer review.
(Photos syndicated via Reuters)
This story has been edited by BH staff and is published from a syndicated field.